California, USA-based Affymetrix says that fellow US firm Wyeth has signed an agreement to continue using its GeneChip microarray technology in research applications for a further three years. The firm added that the extension builds on a deal that was established by the two companies in 1994.
Under the terms of the accord, Wyeth will employ Affymetrix' technology in a wide range of its drug discovery and development programs, specifically in the identification of new drug targets and genetic markers. Financial terms of the deal were not disclosed.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze